NASDAQ:INBX Inhibrx (INBX) Stock Price, News & Analysis → No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free (From Hedgeye) (Ad) Free INBX Stock Alerts $16.65 +0.41 (+2.52%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$16.15▼$17.2050-Day Range$16.24▼$35.0852-Week Range$15.25▼$18.95Volume343,871 shsAverage Volume456,184 shsMarket Capitalization$872.49 millionP/E RatioN/ADividend YieldN/APrice Target$27.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Inhibrx alerts: Email Address Inhibrx MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside62.2% Upside$27.00 Price TargetShort InterestHealthy3.91% of Shares Sold ShortDividend StrengthN/ASustainability-1.21Upright™ Environmental ScoreNews Sentiment1.02Based on 13 Articles This WeekInsider TradingSelling Shares$10.29 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.70 out of 5 starsMedical Sector51st out of 904 stocksBiological Products, Except Diagnostic Industry5th out of 150 stocks 3.0 Analyst's Opinion Consensus RatingInhibrx has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageInhibrx has received no research coverage in the past 90 days.Read more about Inhibrx's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.91% of the outstanding shares of Inhibrx have been sold short.Short Interest Ratio / Days to CoverInhibrx has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inhibrx has recently decreased by 6.39%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldInhibrx does not currently pay a dividend.Dividend GrowthInhibrx does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInhibrx has received a 71.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Clinical research services for deficiency diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Inhibrx is -1.21. Previous Next 3.9 News and Social Media Coverage News SentimentInhibrx has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Inhibrx this week, compared to 1 article on an average week.Search Interest3 people have searched for INBX on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Inhibrx to their MarketBeat watchlist in the last 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inhibrx insiders have sold 932.36% more of their company's stock than they have bought. Specifically, they have bought $996,749.00 in company stock and sold $10,290,000.00 in company stock.Percentage Held by Insiders22.20% of the stock of Inhibrx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.46% of the stock of Inhibrx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Inhibrx's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Inhibrx is -3.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inhibrx is -3.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInhibrx has a P/B Ratio of 75.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. About Inhibrx Stock (NASDAQ:INBX)Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Read More INBX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INBX Stock News HeadlinesJune 8 at 8:30 AM | insidertrades.comInhibrx, Inc. (NASDAQ:INBX) Director Purchases $996,748.68 in StockMay 31, 2024 | insidertrades.comInhibrx, Inc. (NASDAQ:INBX) Insider Brendan P. Eckelman Sells 300,000 SharesJune 8 at 8:32 AM | americanbankingnews.comInhibrx, Inc. (NASDAQ:INBX) Director Jon Faiz Kayyem Purchases 57,549 Shares of StockJune 7 at 2:42 PM | seekingalpha.comInhibrx: Continued Advancement Even After INBRX-101 Sale To SanofiJune 6 at 7:58 AM | americanbankingnews.comInhibrx (NASDAQ:INBX) Shares Gap Up to $18.02June 5, 2024 | benzinga.comTop 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)June 3, 2024 | americanbankingnews.comInhibrx, Inc. (NASDAQ:INBX) Sees Significant Decline in Short InterestJune 2, 2024 | americanbankingnews.comInhibrx, Inc. (NASDAQ:INBX) Insider Sells $10,290,000.00 in StockJune 2, 2024 | americanbankingnews.comInhibrx (NASDAQ:INBX) Shares Gap Down on Insider SellingMay 25, 2024 | finanznachrichten.deInhibrx, Inc.: Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to SanofiMay 24, 2024 | prnewswire.comInhibrx Inc. Stockholders Approve Sale of INBRX-101 to SanofiMay 10, 2024 | finance.yahoo.comInhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-OffMay 10, 2024 | prnewswire.comInhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-OffMay 9, 2024 | businesswire.comINHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBXMay 8, 2024 | prnewswire.comInhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated MergerApril 16, 2024 | msn.comAs more rare disease therapies launch, their prices are risingMarch 16, 2024 | finance.yahoo.comINBX Apr 2024 50.000 putMarch 16, 2024 | finance.yahoo.comINBX Apr 2024 55.000 callFebruary 29, 2024 | realmoney.thestreet.comInhibrx just downgraded at Jefferies, here's whyFebruary 28, 2024 | finanznachrichten.deInhibrx, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsFebruary 28, 2024 | prnewswire.comInhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsFebruary 10, 2024 | businesswire.comINHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBXFebruary 10, 2024 | businesswire.comINHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBXJanuary 24, 2024 | msn.comSanofi signs agreement to acquire Inhibrx for $1.7bnJanuary 24, 2024 | finance.yahoo.comBiotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & MoreSee More Headlines Receive INBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today6/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:INBX CUSIPN/A CIK1739614 Webwww.inhibrx.com Phone858-795-4220FaxN/AEmployees166Year FoundedN/APrice Target and Rating Average Stock Price Target$27.00 High Stock Price Target$27.00 Low Stock Price Target$27.00 Potential Upside/Downside+62.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-241,360,000.00 Net Margins-13,408.95% Pretax Margin-15,115.99% Return on Equity-678.51% Return on Assets-91.73% Debt Debt-to-Equity Ratio17.68 Current Ratio3.82 Quick Ratio3.82 Sales & Book Value Annual Sales$1.63 million Price / Sales533.96 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book75.68Miscellaneous Outstanding Shares52,402,000Free Float40,769,000Market Cap$872.49 million OptionableOptionable Beta2.87 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Mark Paul Lappe (Age 57)Founder, Chairman, President & CEO Comp: $1.1MDr. Brendan P. Eckelman Ph.D. (Age 45)Founder & Chief Scientific Officer Comp: $769.25kMs. Kelly Devine Deck B.S. (Age 44)CPA, M.S., Executive VP & CFO Comp: $636.87kMr. Quinn L. DeverauxFounderDr. Ashraf Amanullah (Age 56)Executive VP & Chief Technical Operations Officer Ms. Leah Pollema J.D.VP, Corporate Secretary & General CounselDr. Charbel Helaihel Pharm.D.Vice President of Marketing & Commercial PlanningMr. Jeffrey J. JensenExecutive VP & Chief Clinical Operations OfficerMr. David Matly M.B.A.Executive VP and Chief Commercial & Business Development OfficerDr. Carlos Bais Ph.D.Executive Vice President of Translational SciencesMore ExecutivesKey CompetitorsDenali TherapeuticsNASDAQ:DNLISpringWorks TherapeuticsNASDAQ:SWTXArcellxNASDAQ:ACLXTwist BioscienceNASDAQ:TWSTApogee TherapeuticsNASDAQ:APGEView All CompetitorsInsiders & InstitutionsJon Faiz KayyemBought 57,549 shares on 6/5/2024Total: $996,748.68 ($17.32/share)Brendan P EckelmanSold 300,000 sharesTotal: $10.29 M ($34.30/share)RA Capital Management L.P.Sold 2,094,370 shares on 5/17/2024Ownership: 5.019%California State Teachers Retirement SystemSold 557 shares on 5/16/2024Ownership: 0.043%Black Maple Capital Management LPBought 15,863 shares on 5/16/2024Ownership: 0.030%View All Insider TransactionsView All Institutional Transactions INBX Stock Analysis - Frequently Asked Questions Should I buy or sell Inhibrx stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inhibrx in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" INBX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INBX, but not buy additional shares or sell existing shares. View INBX analyst ratings or view top-rated stocks. What is Inhibrx's stock price target for 2024? 2 Wall Street analysts have issued twelve-month target prices for Inhibrx's shares. Their INBX share price targets range from $27.00 to $27.00. On average, they predict the company's stock price to reach $27.00 in the next twelve months. This suggests a possible upside of 62.2% from the stock's current price. View analysts price targets for INBX or view top-rated stocks among Wall Street analysts. How have INBX shares performed in 2024? Inhibrx's stock was trading at $38.00 at the beginning of the year. Since then, INBX stock has decreased by 56.2% and is now trading at $16.65. View the best growth stocks for 2024 here. Are investors shorting Inhibrx? Inhibrx saw a decrease in short interest in May. As of May 15th, there was short interest totaling 2,050,000 shares, a decrease of 6.4% from the April 30th total of 2,190,000 shares. Based on an average daily volume of 544,300 shares, the days-to-cover ratio is presently 3.8 days. View Inhibrx's Short Interest. How were Inhibrx's earnings last quarter? Inhibrx, Inc. (NASDAQ:INBX) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.06. The business earned $2.53 million during the quarter, compared to analyst estimates of $1 million. Inhibrx had a negative net margin of 13,408.95% and a negative trailing twelve-month return on equity of 678.51%. What ETFs hold Inhibrx's stock? ETFs with the largest weight of Inhibrx (NASDAQ:INBX) stock in their portfolio include IQ Merger Arbitrage ETF (MNA).iShares Micro-Cap ETF (IWC). What other stocks do shareholders of Inhibrx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inhibrx investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Vivint Solar (VSLR), Activision Blizzard (ATVI), Daqo New Energy (DQ), Fastly (FSLY), Innovative Industrial Properties (IIPR), Lovesac (LOVE) and Micron Technology (MU). When did Inhibrx IPO? Inhibrx (INBX) raised $102 million in an initial public offering on Wednesday, August 19th 2020. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse acted as the underwriters for the IPO and LifeSci Capital was co-manager. Who are Inhibrx's major shareholders? Inhibrx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (5.02%), Vanguard Group Inc. (3.56%), MMCAP International Inc. SPC (0.86%), Russell Investments Group Ltd. (0.36%), Platinum Investment Management Ltd. (0.28%) and Swiss National Bank (0.08%). Insiders that own company stock include Brendan P Eckelman, Global Investors Lp Viking, Jon Faiz Kayyem and Mark Lappe. View institutional ownership trends. How do I buy shares of Inhibrx? Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INBX) was last updated on 6/9/2024 by MarketBeat.com Staff From Our PartnersUrgent alert: open this for a huge profit potentialThis groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...Timothy Sykes | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.